933 patents
Page 17 of 47
Utility
Methods and Assemblies for Preparing and Dispensing Lyospheres of Pharmaceutical Compositions
25 Aug 22
Disclosed herein are methods for preparing and/or dispensing lyospheres of pharmaceutical compositions of biologics (e.g., vaccines, therapeutic proteins such as monoclonal antibodies) or small molecules (e.g., chemical compounds).
Akhilesh Bhambhani, Morrisa Jones, Derrick M. Smith, David S. Thiriot, Joseph M. Rock
Filed: 23 Jul 20
Utility
Process for Separating Antigen-Binding Polypeptide Monomers Comprising One or More Immunoglobulin Single Variable Domains from Aggregates of Said Monomers
25 Aug 22
A method that uses Protein A chromatography to separate antigen-binding polypeptide monomers comprising one or more immunoglobulin single variable domains (ISVDs) from aggregates of said monomers is disclosed.
Ehsan Allah Espah Borujeni, William J. Rayfield, Sandra E. Rios
Filed: 22 Jun 20
Utility
Methods of Separating Host Cell Lipases from a Production Protein In Chromatographic Processes
25 Aug 22
Provided herein are methods of separating host cell lipases from a production protein in chromatographic processes and methods of improving polysorbate-80 stability in a production protein formulation by separating host cell lipases from the production protein using chromatographic processes.
Rebecca A. Chmielowski, Francis K. Insaidoo, Justin B. Miller, David J. Roush, Darshini Shah, John P. Welsh
Filed: 24 Jul 19
Utility
P53 Activator Peptidomimetic Macrocycles
25 Aug 22
Peptidomimetic macrocycles that comprise all-D configuration ?-amino acids and bind mouse double minute 2 (MDM2 aka E3 ubiquitin-protein ligase) and MDMX (aka MDM4) are described.
Pietro Aronica, Christopher J. Brown, Fernando J. Ferrer, Charles W. Johannes, Srinivasaraghavan Kannan, David P. Lane, Anthony W. Partridge, Tomi K. Sawyer, Yaw Sing Tan, Chandra S. Verma, Tsz Ying Yuen
Filed: 16 Jun 20
Utility
Drug delivery system for the delivery of antiviral agents
23 Aug 22
This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs.
Stephanie Elizabeth Barrett, Marian E. Gindy, Li Li, Ryan S. Teller, Seth P. Forster
Filed: 5 Apr 18
Utility
Automated parasite analysis system
23 Aug 22
A parasite analysis system includes a pressure vessel configured to store a biological sample, an imaging cell connected to the pressure vessel, and a waste depository connected to the imaging cell.
Pavel Vácha, Petr Jankuj, Richard Josef Marhoefer, Václav Belák, Jind{hacek over (r)}ich Soukup, Brunhilde Schölzke, Britta von Oepen
Filed: 14 Jun 19
Utility
ANTI-LAG3 Antibodies and Antigen-binding Fragments
18 Aug 22
The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments.
Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
Filed: 11 Feb 22
Utility
Blood Biomarker and Genetic Markers Associated with Response to CRTH2 Receptor Antagonists
18 Aug 22
The present invention provides a blood biomarker and genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists.
Devan V. Mehrotra, George Philip, Peter M. Shaw
Filed: 28 Apr 20
Utility
Tetracyclic Heterocycle Compounds Useful As Hiv Integrase Inhibitors
18 Aug 22
Timothy John Hartingh, John A. McCauley, Tao Yu, Yonglian Zhang
Filed: 14 Feb 22
Utility
1-PYRAZOLYL, 5-, 6- Disubstituted Indazole Derivatives As LRRK2 Inhibitors, Pharmaceutical Compositions, and Uses Thereof
18 Aug 22
The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein.
Hua Zhou, John J. Acton, III, Michael J. Ardolino, Yi-Heng Chen, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, William P. Kaplan, Solomon D. Kattar, Mitchell H. Keylor, Derun Li, Kaitlyn Marie Logan, Min Lu, Gregori J. Morriello, Santhosh F. Neelamkavil, Barbara Pio, Nunzio Sciammetta, Vladimir Simov, Jing Su, Luis Torres, Xin Yan
Filed: 1 Jun 20
Utility
Coccidiosis vaccine
16 Aug 22
Colin Crouch
Filed: 26 Jun 20
Utility
Tricyclic heterocycle compounds useful as HIV integrase inhibitors
16 Aug 22
Mark W. Embrey, Timothy John Hartingh, Marc Labroli, Izzat T. Raheem
Filed: 11 Feb 19
Utility
Conjugate based systems for controlled insulin delivery
16 Aug 22
The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain).
Chris Moyes, Songnian Lin
Filed: 13 Dec 18
Utility
Containment System for Mixing Dry Powders with Solvents During Drug Production or Processing
11 Aug 22
A solids charging containment apparatus and method for mixing a solvent with a dry powder, comprising a dual compartment isolator for safely removing the dry powder from a dry powder container, a mixing vessel, and a negative cascading pressure controller.
John H. Roosa, Alan S. D'Alessandro, Robert O'Connor, Luke Schenck, Timothy Stanoch
Filed: 15 Jun 20
Utility
ANTI-PD-1/LAG3/TIGIT Trispecific Antibodies and ANTI-PD-1/LAG3 Bicpecific Antibodies
11 Aug 22
Provided herein are treatments of conditions ameliorated by counteracting tumor mediated immune suppression.
Laurence Fayadat-Dilman, Veronica Juan, Robert A. Kastelein
Filed: 28 Jul 20
Utility
Compositions of Programmed Death Receptor 1 (PD-1) Antibodies and Methods of Obtaining the Compositions Thereof
11 Aug 22
The invention provides compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0% oxidation of Met105 in the CDRH3 heavy chain region, and methods of obtaining the purified compositions.
Mark A. Brower, Chung-Jr Huang, Brian Wai Kwan, William Nicholas Napoli, Bhumit A. Patel, Nuno J. Dos Santos Pinto, Douglas Dennis Richardson, II, Sen Xu
Filed: 27 Jan 22
Utility
Caninized Antibodies to Human CTLA-4
11 Aug 22
The present invention provides caninized anti-human CTLA-4 antibodies that have specific sequences and a high binding affinity for canine CTLA-4.
Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
Filed: 15 Jul 20
Utility
Caninized Antibodies Against Canine CTLA-4
11 Aug 22
The present invention provides caninized murine antibodies against canine CTLA-4 that have specific sequences and a high binding affinity for canine CTLA-4.
Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
Filed: 15 Jul 20
Utility
Compounds for the treatment of bovine or swine respiratory disease
9 Aug 22
The present invention provides compounds for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
Thorsten Meyer, Ralf Warrass, Joachim Ullrich, Michael Berger, Michael Linder
Filed: 22 Dec 17
Utility
Recombinant expression of
9 Aug 22
The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter.
Lan Zhang, Zhiyun Wen, Craig T. Przysiecki, Ping Qiu
Filed: 8 Jun 20